NBIX Neurocrine Biosciences Inc.

+2.36  (+2%)
Previous Close 94.88
Open 95.9
Price To Book 18.42
Market Cap 8,905,180,953
Shares 91,579,401
Volume 413,453
Short Ratio
Av. Daily Volume 643,308

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 initiation 2Q/3Q 2019.
Congenital Adrenal Hyperplasia (CAH) - children
Pivotal trial to be initiated pending talks with FDA in 3Q 2019.
Congenital Adrenal Hyperplasia (CAH) - adults
Approval for sNDA 80 mg capsules announced October 5, 2017.
Tardive dyskinesia
PDUFA date April 26, 2020.
Parkinson's disease
Phase 2 top-line data released December 12, 2018 did not meet primary endpoint.
Tourette syndrome - juvenile
Phase 2 data released January 18, 2017 did not meet primary endpoint.
Tourette syndrome - adults
NDA filing announced August 5, 2019.
Uterine Fibroids
FDA approval announced July 24, 2018.
Approved April 11, 2017.
Tardive dyskinesia
Phase 2 trial ongoing. Evaluating next steps.
Tourette syndrome - pediatric

Latest News

  1. Why Neurocrine (NBIX) Could Be Positioned for a Surge
  2. Moving Average Crossover Alert: Neurocrine Biosciences
  3. Spectrum Pharma's (SPPI) Loss Narrows in Q2, Stock Rises
  4. Zoetis (ZTS) Hits Fresh High: Is There Still Room to Run?
  5. Achillion (ACHN) Reports Wider Y/Y Loss in Q2, Revenues Nil
  6. Esperion (ESPR) Q2 Loss Wider Than Expected, Revenues Beat
  7. Neurocrine Biosciences Inc (NBIX) CEO Kevin Charles Gorman Sold $7.6 million of Shares
  8. Jazz Pharma (JAZZ) Q2 Earnings and Sales Beat Estimates
  9. AbbVie Submits New Drug Application to US FDA for Investigational Elagolix for Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids in Women
  10. Edited Transcript of NBIX earnings conference call or presentation 29-Jul-19 8:30pm GMT
  11. Steven Cohen Charges Into Chiasma
  12. Why Neurocrine (NBIX) Might be Well Poised for a Surge
  13. Why Neurocrine Biosciences Stock Is Jumping Today
  14. Dow Jones Futures: Beyond Meat Leads 5 Key Movers; Apple Earnings Loom
  15. Neurocrine Biosciences Posts Sizzling Sales Growth in Q2
  16. Neurocrine Biosciences Inc (NBIX) Q2 2019 Earnings Call Transcript
  17. Neurocrine Biosciences (NBIX) Q2 Earnings and Revenues Top Estimates
  18. Neurocrine Biosciences Reports Second Quarter 2019 Financial Results
  19. Should You Buy Neurocrine (NBIX) Ahead of Earnings?
  20. 8 Health-Care Stocks for Your Portfolio